IBN SINA PHARMACEUTICALS LTD.
It is mainly used for the symptomatic treatment of nausea and vertigo due to Meniere's disease and other labyrinthine disturbances and for the prevention and treatment of motion sickness. It is also used in the management of various vascular disorders. Cerebral circulatory disorders: Prophylaxis and maintenance therapy for symptoms of cerebral vascular spasms and arteriosclerosis such as dizziness, ear buzzing (tinnitus), vascular headache, unsociability and irritability, fatigue, sleep rhythm disorders such as premature awakening, involutional depressions, loss of memory and lack of concentration, incontinence and other disorders due to aging. Sequel of cerebral and cranial trauma. Post-apoplectic disorders. Migraine. Peripheral circulatory disorders: Prophylaxis and maintenance therapy for symptoms of vascular spasms and arteriosclerosis (obliterating arteritis, thromboangitis obliterans, Raynaud's disease, diabetes, acrocyanosis, perrio, etc.) such as: intermittent claudication, trophic disturbances, pregangrene, trophic and varicose ulcers, paraesthesia, nocturnal cramps, cold extremities. Disorders of balance: Prophylaxis and maintenance therapy for symptoms of labyrinthine arteriosclerosis, vestibular irritability, Meniere's syndrome, such as vertigo, dizziness, giddiness, syncopal attacks, tinnitus, nystagmus, nausea and vomiting. Prophylaxis of motion sickness.
Anti vertigo drugs
Cinnarizine acts as an antihistamine, labyrinthine sedative and a peripheral antivasoconstrictor. Inarzin is a selective calcium antagonist, inhibiting the influx of Ca2+ intracellularly. It prevents the Ca2+ dependent contraction of arterial smooth muscle by inhibiting Ca2+ influx through smooth muscle calcium channels and thereby, improves vestibular symptoms and prevents peripheral arterial disease
Peripheral vascular disease: Adult: 75 mg bid or tid. Cerebrovascular disorders: Adult: 75 mg once daily. Motion sickness: Adult: 30 mg 2 hr before travel then 15 mg 8 hrly during the journey if necessary. Child: 5-12 yr 15 mg 2 hr before travel then 7.5 mg 8 hrly during the journey as necessary. Vertigo and vestibular disorders: Adult: 30 mg tid or 75 mg 1-2 times daily. Child: 5-12 yr 15 mg tid.
Concurrent use of alcohol, CNS depressants or tricyclic antidepressants may potentiate the sedative effects of either these drugs or of Cinnarizine. Therefore, it is advisable to avoid these drugs while taking Cinnarizine.
Contraindicated in Known hypersensitivity to Cinnarizine, Parkinson8s disease, Hypotension
Side effects such as somnolence and gastrointestinal disturbances are extremely rare. They are transient and may be readily prevented by achieving the optimal dosage gradually. Combination therapy with other drugs is possible. Whenever indicated, caution should be taken in hypotension (high doses). Rarely, extrapyramidal symptoms in elderly on prolonged therapy.
Pregnancy Category C. The safety of Cinnarizine in human pregnancy has not been established. Therefore, it is not advisable to administer Cinnarizine in pregnancy. Lactation: It is not known if Cinnarizine is excreted in human breast milk. Use of Cinnarizine during breast feeding is not advised.
Symptoms: Consciousness alterations ranging from somnolence to stupor and coma, vomiting, extrapyramidal symptoms, hypotonia; seizures may occur in young children. Management: Symptomatic and supportive treatment. May consider admin of activated charcoal within 1 hr of ingestion.
Patient with hypotension (high dose), Parkinson's disease, porphyria. Renal and hepatic impairment. Childn. Pregnancy and lactation.